MAPT and Alzheimer disease: According to that proposal, biomarker abnormalities of β-amyloid protein and phospho-tau protein in the CSF, or neuroimaging or plasma, should be diagnosed as AD or as “biological AD,” even in the absence of any clinical symptom.33